Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease

Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease PR Newswire MOUNTAIN VIEW, California, June 12, 2012 - The company's unique Vas Zeppelin catheter-based microsurgery technology platform combines the strengths of various treatment approaches while minimizing associated risks MOUNTAIN VIEW, California, June 12, 2012 /PRNewswire/ -- Based on its recent analysis of the pulmonary disease treatment market, Frost & Sullivan recognizes Sanovas, Inc. with the 2012 North American Frost & Sullivan Award for New Product Innovation. Sanovas's pioneering Vas Zeppelin microsurgery technology platform represents a major leap forward in the tools available to diagnose and treat lung cancer and other airway obstructions. The increasing incidence of pulmonary disease has already reached epidemic proportions. Due to the lack of effective treatment and curative solutions, the vast majority of treatment costs go toward palliative care services that provide no chance of recovery and minimal quality-of-life enhancement for patients. The lack of effective options for this highly under-served patient population underscores the need for novel and innovative approaches. "Given the unique anatomical structure of the lungs, most existing treatment options including surgery, chemotherapy, and radiation come with major trade- offs," says Venkat Rajan, Frost & Sullivan's industry manager for advanced medical technologies.